Claims for Patent: 4,996,335
✉ Email this page to a colleague
Summary for Patent: 4,996,335
| Title: | Soft steroids having anti-inflammatory activity |
| Abstract: | The invention provides novel soft steroidal anti-inflammatory agents, pharmaceutical compositions containing said agents, and methods of administering same to mammals in the treatment of inflammation. Preferred compounds of the invention include haloalkyl 17.alpha.-alkoxycarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-ca rboxylates and the corresponding .DELTA..sup.1,4 compounds, optionally bearing 6.alpha.- and/or 9.alpha.-fluorine and 16.alpha.- or 16.beta.-methyl substituents. Especially preferred compounds include haloalkyl 17.alpha.-alkoxycarbonyloxy-9.alpha.-fluoro-11.beta.-hydroxy-16-methylandr osta-1,4-dien-3-one-17.beta.-carboxylates. |
| Inventor(s): | Bodor; Nicholas S. (Gainesville, FL) |
| Assignee: | Bodor; Nicholas S. (Gainesville, FL) |
| Application Number: | 06/807,034 |
| Patent Claims: |
1. A compound selected from the group consisting of:
(a) a compound of the formula ##STR243## wherein: R.sub.1 is C.sub.1 -C.sub.10 alkyl; C.sub.2 -C.sub.10 (monohydroxy or polyhydroxy)alkyl; C.sub.1 -C.sub.10 (monohalo or polyhalo)alkyl; or --CH.sub.2 COOR.sub.6 wherein R.sub.6 is unsubstituted or substituted C.sub.1 -C.sub.10 alkyl; C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkenyl or C.sub.2 -C.sub.10 alkenyl, the substituents being selected from the group consisting of halo, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, ##STR244## or R.sub.6 is unsubstituted or substituted phenyl or benzyl, the substituents being selected from the group consisting of lower alkyl, lower alkoxy, halo, carabamoyl, lower alkoxycarbonyl, lower alkanoyloxy, lower haloalkyl, mono(lower alkyl)amino, di(lower alkyl)amino, mono(lower alkyl)carbamoyl, di(lower alkyl)carbamoyl, lower alkylthio, lower alkylsulfinyl and lower alkylsulfonyl; or R.sub.1 is --CH.sub.2 CONR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8, which can be the same or different, are each hydrogen, lower alkyl, C.sub.3 -C.sub.8 cycloalkyl, phenyl or benzyl, or R.sub.7 and R.sub.8 are combined such that --NR.sub.7 R.sub.8 represents the residue of a saturated monocyclic secondary amine; or R.sub.1 is unsubstituted or substituted phenyl or benzyl, the substituents being selected from the group of phenyl and benzyl substituents defined hereinabove with respect to R.sub.6 ; or R.sub.1 is ##STR245## wherein Y is --S--, --SO--, --SO.sub.2 -- or --O-- and R.sub.9 is hydrogen, lower alkyl or phenyl, or R.sub.9 and the lower alkyl group adjacent to Y are combined so that R.sub.1 is a cyclic system of the type ##STR246## wherein Y is defined as above and the alkylene group contains 3 to 10 carbon atoms, of which at least 3 and no more than 6 are ring atoms; or R.sub.1 is ##STR247## wherein R.sub.6 is defined as hereinabove and R.sub.10 is hydrogen, lower alkyl, phenyl or halophenyl; R.sub.2 is unsubstituted or substituted C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkenyl or C.sub.2 -C.sub.10 alkenyl, the substituents being selected from the group consisting of halo, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, ##STR248## or R.sub.2 is unsubstituted or substituted phenyl or benzyl, the substituents being selected from the group consisting of lower alkyl, lower alkoxy, halo, carbamoyl, lower alkoxycarbonyl, lower alkanoyloxy, lower haloalkyl, mono(lower alkyl)amino, di(lower alkyl)amino, mono(lower alkyl)carbamoyl, di(lower alkyl)carbamoyl, lower alkylthio, lower alkylsulfinyl and lower alkylsulfonyl; R.sub.3 is hydrogen, .alpha.-hydroxy, .beta.-hydroxy, .alpha.-methyl, .beta.-methyl, .dbd.CH.sub.2, or .alpha.- or ##STR249## wherein R.sub.2 is identical to R.sub.2 as defined hereinabove; R.sub.4 is hydrogen, fluoro or chloro; R.sub.5 is hydrogen, fluoro, chloro or methyl; X is --O-- or --S--; and the dotted line in ring A indicates that the 1,2 linkage is saturated or unsaturated; (b) a quaternary ammonium salt of a compound of formula (I) wherein at least one of R.sub.1 and R.sub.2 is a halo-substituted alkyl group; (c) a compound of the formula ##STR250## wherein R.sub.2, R.sub.4, R.sub.5, and the dotted line in ring A are as defined in (a) above, Z is carbonyl or .beta.-hydroxymethylene and R.sub.3 " is hydrogen, .alpha.-methyl, .beta.-methyl, .dbd.CH.sub.2 or .alpha.- or ##STR251## wherein R.sub.2 is identical to R.sub.2 above; (d) a compound of the formula ##STR252## wherein M is alkali metal, thallium, alkaline earth metal/2 or NH.sub.4 and R.sub.2, R.sub.3 ", R.sub.4, R.sub.5, Z and the dotted line in ring A are as defined in (a) and (c) above; (e) a compound of the formula ##STR253## wherein R.sub.3 "' is hydrogen, .alpha.-methyl, .beta.-methyl, .alpha.-OCOCl or .beta.-OCOCl, and R.sub.1, R.sub.4, R.sub.5, Z and the dotted line in ring A are as defined in (a) and (c) above; (f) a compound of the formula ##STR254## wherein R.sub.2, R.sub.3 ", R.sub.4, R.sub.5, Z and the dotted line in ring A are as defined in (a) and (c) above; and (g) a compound of the formula ##STR255## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X and the dotted line in ring A are as defined in (a) above. 2. A compound selected from the group consisting of: (a) a compound of the formula ##STR256## wherein: R.sub.1 is C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl; --CH.sub.2 COOR.sub.6 wherein R.sub.6 is C.sub.1 -C.sub.6 alkyl; --CH.sub.2 --Y--(C.sub.1 -C.sub.6 alkyl) wherein Y is --S--, --SO--, --SO.sub.2 -- or --O--; or ##STR257## wherein R.sub.6 ' is C.sub.1 -C.sub.6 or phenyl; R.sub.2 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, phenyl, benzyl or C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl; R.sub.3 is hydrogen, .alpha.-hydroxy, .beta.-methyl, .beta.-methyl or ##STR258## wherein R.sub.2 is identical to R.sub.2 as defined hereinabove; R.sub.4 is hydrogen or fluoro; R.sub.5 is hydrogen or fluoro; X is --O--; and the dotted line in ring A indicates that the 1,2-linkage is saturated or unsaturated; (b) a quaternary ammonium salt of a compound of formula (I) wherein at least one of R.sub.1 and R.sub.2 is a halo-substituted alkyl group; (c) a compound of the formula ##STR259## wherein R.sub.2, R.sub.4, R.sub.5 and the dotted line in ring A are as defined in (a) above, Z is carbonyl or .beta.-hydroxymethylene and R.sub.3 " is hydrogen, .alpha.-methyl, .beta.-methyl or ##STR260## wherein R.sub.2 is identical to R.sub.2 above; (d) a compound of the formula ##STR261## wherein M is alkali metal, thallium, alkaline earth metal/2 or NH.sub.4 and R.sub.2, R.sub.3 ", R.sub.4, R.sub.5, Z and the dotted line in ring A are as defined in (a) and (c) above; (e) a compound of the formula ##STR262## wherein R.sub.3 "' is hydrogen, .alpha.-methyl, .beta.-methyl or .alpha.-OCOCl, and R.sub.1, R.sub.4, R.sub.5, Z and the dotted line in ring A are as defined in (a) and (c) above; (f) a compound of the formula ##STR263## wherein R.sub.2, R.sub.3 ", R.sub.4, R.sub.5, Z and the dotted line in ring A are as defined in (a) and (c) above; and (g) a compound of the formula ##STR264## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X and the dotted line in ring A are as defined in (a) above. 3. A compound of claim 1 or 2, said compound having the structural formula (I). 4. A compound of claim 1 or 2, said compound being a quaternary ammonium salt of a compound of formula (I) wherein at least one of R.sub.1 and R.sub.2 is a halo-substituted alkyl group. 5. A compound of claim 1 or 2, said compound having the structural formula (III). 6. A compound of claim 1 or 2, said compound having the structural formula (IV). 7. A compound of claim 1 or 2, said compound having the structural formula (VII). 8. A compound of claim 1 or 2, said compound having the structural formula (VIII). 9. A compound of claim 1 or 2, said compound having the structural formula (IX). 10. A compound of claim 1, said compound having the structural formula (I) wherein R.sub.3 is hydrogen, .alpha.-methyl, .beta.-methyl, .dbd.CH.sub.2 or .alpha.- or ##STR265## 11. A compound of claim 1 or 2, said compound having the structural formula (I) wherein R.sub.1 is C.sub.1 -C.sub.6 alkyl. 12. A compound of claim 1 or 2, said compound having the structural formula (I) wherein R.sub.1 is C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl. 13. A compound of claim 12 wherein C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl is C.sub.1 -C.sub.6 monohaloalkyl. 14. A compound of claim 13 wherein C.sub.1 -C.sub.6 monohaloalkyl is C.sub.1 -C.sub.6 monochloroalkyl. 15. A compound of claim 14 wherein C.sub.1 -C.sub.6 monochloroalkyl is chloromethyl. 16. A compound of claim 11 wherein R.sub.2 is C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 monohaloalkyl. 17. A compound of claim 12 wherein R.sub.2 is C.sub.1 -C.sub.6 alkyl. 18. A compound of claim 13 wherein R.sub.2 is C.sub.1 -C.sub.6 alkyl. 19. A compound of claim 14 wherein R.sub.2 is C.sub.1 -C.sub.6 alkyl. 20. A compound of claim 15 wherein R.sub.2 is C.sub.1 -C.sub.6 alkyl. 21. A compound of claim 11 wherein R.sub.2 is C.sub.3 -C.sub.8 cycloalkyl, phenyl, benzyl or C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl. 22. A compound of claim 12 wherein R.sub.2 is C.sub.3 -C.sub.8 cycloalkyl, phenyl, benzyl or C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl. 23. A compound of claim 13 wherein R.sub.2 is C.sub.3 -C.sub.8 cycloalkyl, phenyl, benzyl or C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl. 24. A compound of claim 14 wherein R.sub.2 is C.sub.3 -C.sub.8 cycloalkyl, phenyl, benzyl or C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl. 25. A compound of claim 15 wherein R.sub.2 is C.sub.3 -C.sub.8 cycloalkyl, phenyl, benzyl or C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl. 26. A compound of claim 1, said compound having the structural formula (I) wherein X is --O--. 27. A compound of claim 12 wherein X is --O--. 28. A compound of claim 13 wherein X is --O--. 29. A compound of claim 14 wherein X is --O--. 30. A compound of claim 17 wherein R.sub.4 and R.sub.5 are hydrogen. 31. A compound of claim 18 wherein R.sub.4 and R.sub.5 are hydrogen. 32. A compound of claim 19 wherein R.sub.4 and R.sub.5 are hydrogen. 33. A compound of claim 20 wherein R.sub.4 and R.sub.5 are hydrogen. 34. A compound of claim 17 wherein at least one of R.sub.4 and R.sub.5 is fluoro. 35. A compound of claim 18 wherein at least one of R.sub.4 and R.sub.5 is fluoro. 36. A compound of claim 19 wherein at least one of R.sub.4 and R.sub.5 is fluoro. 37. A compound of claim 20 wherein at least one of R.sub.4 and R.sub.5 is fluoro. 38. A compound of claim 17 wherein R.sub.4 is fluoro and R.sub.5 is hydrogen. 39. A compound of claim 18 wherein R.sub.4 is fluoro and R.sub.5 is hydrogen. 40. A compound of claim 19 wherein R.sub.4 is fluoro and R.sub.5 is hydrogen. 41. A compound of claim 20 wherein R.sub.4 is fluoro and R.sub.5 is hydrogen. 42. A compound of claim 35 wherein R.sub.3 is .alpha.-methyl or .beta.-methyl. 43. A compound of claim 37 wherein R.sub.3 is .alpha.-methyl or .beta.-methyl. 44. A compound of claim 39 wherein R.sub.3 is .alpha.-methyl or .beta.-methyl. 45. A compound of claim 41 wherein R.sub.3 is .alpha.-methyl or .beta.-methyl. 46. A compound of claim 1 or 2, said compound having the structural formula (I) wherein R.sub.1 is --CH.sub.2 COOR.sub.6, --CH.sub.2 --Y--(C.sub.1 -C.sub.6 alkyl) or ##STR266## 47. A compound of claim 1, said compound having the structural formula (I) wherein R.sub.1 is --CH.sub.2 CONR.sub.7 R.sub.8. 48. A compound of claim 47 wherein at least one of R.sub.7 and R.sub.8 is hydrogen or C.sub.1 -C.sub.6 alkyl. 49. A compound of claim 47 wherein R.sub.7 and R.sub.8 are combined so that --NR.sub.7 R.sub.8 represents the residue of a saturated monocyclic secondary amine containing 5 to 7 carbon atoms. 50. A compound of claim 49 wherein --NR.sub.7 R.sub.8 representss morpholino, 1-pyrrolidinyl, 4-benzyl-1-piperazinyl, perhydro-1,2,4-oxathiazin-4-yl, 1- or 4-piperazinyl, 4-methyl-1-piperazinyl, piperidino, hexamethyleneimino, 4-phenylpiperidino, 2-methyl-1-pyrazolidinyl, 1- or 2-pyrazolidinyl, 3-methyl-1-imidazolidinyl, 1- or 3-imidazolidinyl, 4-benzylpiperidino or 4-phenyl-1-piperazinyl. 51. A compound of claim 1, said compound having the structural formula (I) wherein R.sub.1 is ##STR267## wherein R.sub.9 is hydrogen or methyl, or wherein R.sub.9 and the lower alkyl group adjacent to Y are combined so that R.sub.1 is ##STR268## wherein Y is --S--, --SO--, --SO.sub.2 -- or --O-- and the alkylene group contains 3 to 10 carbon atoms, of which at least 3 and no more than 6 are ring atoms. 52. A compound of claim 1 or 2, said compound having the structural formula (III) wherein Z is .beta.-hydroxymethylene and R.sub.2 is C.sub.1 -C.sub.6 alkyl. 53. A compound of claim 1 or 2, said compound having the structural formula (IV) wherein Z is .beta.-hydroxymethylene and R.sub.2 is C.sub.1 -C.sub.6 alkyl. 54. A compound of claim 1 or 2, said compound having the structural formula (VII) wherein Z is .beta.-hydroxymethylene and R.sub.1 is C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 monohaloalkyl. 55. A compound of claim 1 or 2, said compound having the structural formula (VIII) wherein Z is .beta.-hydroxymethylene and R.sub.2 is C.sub.1 -C.sub.6 alkyl. 56. A compound of claim 1 or 2, said compound having the structural formula (IX) wherein R.sub.1 is C.sub.1 -C.sub.6 (monohalo or polyhalo) alkyl. 57. A compound of claim 56 wherein C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl is C.sub.1 -C.sub.6 monohaloalkyl. 58. A compound of claim 57 wherein R.sub.2 is C.sub.1 -C.sub.6 alkyl. 59. A compound of claim 1 or 2, said compound having the structural formula (IX) wherein R.sub.1 is C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 monohaloalkyl, R.sub.2 is C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 monohaloalkyl and X is --O--. 60. A compound of claim 2, said compound having the structural formula (IX) wherein R.sub.1 is C.sub.1 -C.sub.6 alkyl, --CH.sub.2 COOR.sub.6, --CH.sub.2 --Y--(C.sub.1 -C.sub.6 alkyl) or ##STR269## 61. The compound of claim 2 which is chloromethyl 11.beta.-hydroxy-17.alpha.-methoxycarbonyloxyandrost-4-en-3-one-17.beta.-c arboxylate. 62. The compound of claim 2 which is chloromethyl 17.alpha.-ethoxycarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-ca rboxylate. 63. The compound of claim 2 which is chloromethyl 17.beta.-butoxycarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-car boxylate. 64. The compound of claim 2 which is chloromethyl 11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxyandrost-4-en-3-one-17.beta .-carboxylate. 65. The compound of claim 2 which is chloromethyl 17.alpha.-ethoxycarbonyloxy-9.alpha.-fluoro-11.beta.-hydroxy-16.beta.-meth ylandrosta-1,4-dien-3-one-17.beta.-carboxylate. 66. The compound of claim 2 which is chloromethyl 9.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-methyl-17.alpha.-propoxycarbony loxyandrosta-1,4-dien-3-one-17.beta.-carboxylate. 67. The compound of claim 2 which is 1-chloroethyl 11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxyandrost-4-en-3-one-17.beta .-carboxylate. 68. The compound of claim 2 which is 1-chloroethyl 9.alpha.-fluoro-11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxy-16.beta.- methylandrosta-1,4-dien-3-one-17.beta.-carboxylate. 69. The compound of claim 2 which is chloromethyl 17.alpha.-ethoxycarbonyloxy-11.beta.-hydroxyandrosta-1,4-dien-3-one-17.bet a.-carboxylate. 70. The compound of claim 2 which is chloromethyl 11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxyandrosta-1,4-dien-3-one-17 .beta.-carboxylate. 71. The compound of claim 2 which is chloromethyl 17.alpha.-ethoxycarbonyloxy-9.alpha.-fluoro-11.beta.-hydroxyandrosta-1,4-d ien-3-one-17.beta.-carboxylate. 72. The compound of claim 2 which is chloromethyl 17.alpha.-ethoxycarbonyloxy-9.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-met hylandrosta-1,4-dien-3-one-17.beta.-carboxylate. 73. The compound of claim 2 is chloromethyl 9.alpha.-fluoro-11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxy-16.alpha. -methylandrosta-1,4-dien-3-one-17.beta.-carboxylate. 74. The compound of claim 2 which is chloromethyl 9.alpha.-fluoro-11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxy-16.beta.- methylandrosta-1,4-dien-3-one-17.beta.-carboxylate. 75. The compound of claim 2 which is chloromethyl 9.alpha.-fluoro-11.beta.-hydroxy-17.alpha.-methoxycarbonyloxy-16.beta.-met hylandrosta-1,4-dien-3-one-17.beta.-carboxylate. 76. The compound of claim 2 which is chloromethyl 9.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-methyl-17.alpha.-pentyloxycarbo nyloxyandrosta-1,4-dien-3-one-17.beta.-carboxylate. 77. The compound of claim 2 which is fluoromethyl 17.alpha.-ethoxycarbonyloxy-9.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-met hylandrosta-1,4-dien-3-one-17.beta.-carboxylate. 78. The compound of claim 2 which is methyl 17.alpha.-(2-chloroethoxy)carbonyloxy-9.alpha.-fluoro-11.beta.-hydroxy-16. alpha.-methylandrosta-1,4-dien-3-one-17.beta.-carboxylate. 79. The compound of claim 2 which is 17.beta.-ethoxycarbonyloxy-9.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-meth ylandrosta-1,4-dien-3-one-17.beta.-carboxylic acid. 80. The compound of claim 2 which is 9.alpha.-fluoro-11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxy-16.beta.- methylandrosta-1,4-dien-3-one-17.beta.-carboxylic acid. 81. The compound of claim 2 which is 9.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-methyl-17.alpha.-propoxycarbony loxyandrosta-1,4-dien-3-one-17.beta.-carboxylic acid. 82. The compound of claim 2 which is 9.alpha.-fluoro-11.beta.-hydroxy-17.alpha.-methoxycarbonyloxy-16.alpha.-me thylandrosta-1,4-dien-3-one-17.beta.-carboxylic acid. 83. The compound of claim 2 which is 11.beta.-hydroxy-17.alpha.-methoxycarbonyloxyandrost-4-en-3-one-17.beta.-c arboxylic acid, 17.alpha.-ethoxycarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-ca rboxylic acid, 17.alpha.-butoxycarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-ca rboxylic acid, or 11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxyandrost-4-en-3-one-17.beta .-carboxylic acid. 84. The compound of claim 2 which is sodium 11.beta.-hydroxy-17.alpha.-methoxycarbonyloxyandrost-4-en-3-one-17.beta.-c arboxylate, sodium 17.alpha.-ethoxycarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-ca rboxylate, sodium 17.alpha.-butoxycarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-ca rboxylate, or sodium 11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxyandrost-4-en-3-one-17.beta .-carboxylate. 85. The compound of claim 2 which is chloromethyl 17.alpha.-chlorocarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-ca rboxylate. 86. The compound of claim 2 which is chloromethyl 17.alpha.-ethoxycarbonyloxy-9.alpha.-fluoro-16.alpha.-methylandrosta-1,4-d ien-3,11-dione-17.beta.-carboxylate. 87. The compound of claim 2 which is chloromethyl 9.alpha.-fluoro-17.alpha.-isopropoxycarbonyloxy-16.beta.-methylandrosta-1, 4-diene-3,11-dione-17.beta.-carboxylate. 88. A pharmaceutical composition of matter comprising an anti-inflammatory effective amount of a compound of claim 1 or 2 having the structural formula (I), in combination with a non-toxic pharmaceutically acceptable carrier therefor suitable for topical or other local application. 89. A method for alleviating inflammation in or on a warm-blooded animal exhibiting a topical inflammatory response, which comprises topically administering thereto an anti-inflammatory effective amount of a composition of claim 88. 90. A method for alleviating inflammation in or on a warm-blooded animal exhibiting a localized inflammatory response, which comprises locally administering thereto an anit-inflammatory effective amount of composition of claim 88. 91. A compound of claim 13 wherein C.sub.1 -C.sub.6 monohaloalkyl is C.sub.1.notident.-C.sub.6 monofluoroalkyl. 92. A compound of claim 91 wherein C.sub.1 -C.sub.6 monofluoroalkyl is fluoromethyl. 93. A compound of claim 91 wherein R.sub.2 is C.sub.1 -C.sub.6 alkyl. 94. A compound of claim 92 wherein R.sub.2 is C.sub.1 -C.sub.6 alkyl. 95. A compound of claim 91 wherein X is --I--. 96. A compound of claim 95 wherein R.sub.4 and R.sub.5 are hydrogen. 97. A compound of claim 96 wherein R.sub.3 is hydrogen. 98. A compound of claim 95 wherein at least one of R.sub.4 and R.sub.5 is fluoro. 99. A compound of claim 95 wherein R.sub.4 is fluoro and R.sub.5 is hydrogen. 100. A compound of claim 99 wherein R.sub.3 is .alpha.-methyl or .beta.-methyl. 101. A compound of claim 2 which is fluoromethyl 11.beta.-hydroxy-17.alpha.-isopropoxycarbonyloxyandrost-4-en-3-one-17.beta .-carboxylate. 102. The compound of claim 2 which is fluoromethyl 17.alpha.-ethoxycarbonyloxy-9.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-met hylandrosta-1,4-dien-3-one-17.beta.-carboxylate. 103. The compound of claim 2 which is fluoromethyl 9.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-methyl-17.alpha.-n-propoxycarbo nyloxyandrosta-1,4-dien-3-one-17.beta.-carboxylate. 104. A compound of claim 1 or 2, said compound having the structural formula (I) wherein R.sub.3, R.sub.4 and R.sub.5 are hydrogen and the 1,2 linkage is saturated or unsaturated. 105. A compound of claim 1 or 2, said compound having the structural formula (I) wherein R.sub.3 is selected from hydrogen or methyl, R.sub.4 is fluoro and R.sub.5 is hydrogen and the 1,2 linkage is saturated or unsaturated. 106. A compound of claim 1 or 2, said compound having the structural formula (I) wherein R.sub.3 is hydrogen or methyl, R.sub.4 is hydrogen or fluoro and R.sub.5 is fluoro or methyl and the 1,2 linkage is unsaturated. 107. A compound of claim 1 or 2, said compound having the structural formula (I) wherein R.sub.3 is ##STR270## and wherein R.sub.4 is fluoro and R.sub.5 is hydrogen and the 1,2 linkage is unsaturated. 108. A compound of claim 59 wherein R.sub.3 is hdyrogen or methyl, R.sub.4 is hydrogen and R.sub.5 is hydrogen or chloro and the 1,2 linkage is saturated or unsaturated. 109. The compound of claim 45 wherein R.sub.3 is .alpha.-methyl and the 1,2 linkage is unsaturated. 110. A compound of the formula ##STR271## wherein R.sub.1 is C.sub.1 -C.sub.6 (monohalo)alkyl, R.sub.2 is C.sub.1 -C.sub.6 alkyl, R.sub.3 is hydrogen, .alpha.-methyl or .beta.-methyl and R.sub.4 is hydrogen or fluoro. 111. A compound of claim 110 wherein R.sub.1 is chloromethyl. 112. A compound of claim 110 wherein R.sub.3 is .alpha.-methyl and R.sub.4 is fluoro. 113. A compound of the formula ##STR272## wherein: R.sub.1 is --CH.sub.2 COOR.sub.6 wherein R.sub.6 is C.sub.1 -C.sub.6 alkyl; --CH.sub.2 --Y--(C.sub.1 -C.sub.6 alkyl) wherein Y is --S--, --SO--, --SO.sub.2 -- or --O--; or ##STR273## wherein R.sub.6 ' is C.sub.1 -C.sub.6 alkyl or phenyl; R.sub.2 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, phenyl, benzyl or C.sub.1 -C.sub.6 (monohalo or polyhalo)alkyl; R.sub.3 is hydrogen, .alpha.-hydroxy, .alpha.-methyl, .beta.-methyl or ##STR274## wherein R.sub.2 is as defined above; R.sub.4 is hydrogen or fluoro; R.sub.5 is hydrogen or fluoro; X is --O-- or --S--; and the dotted line in ring A indicates that the 1,2-linkage is saturated or unsaturated. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
